Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
GenEdit, a US-based genetic medicine developer based on research at University of California (UC), Berkeley, has completed a $26m series A round featuring the UC-aligned venture capital fund Bow Capital. The round also included pharmaceutical firm Eli Lilly, conglomerate SK, KTB Network, Company K Partners, Korea Investment Partners, Dayli Partners, KB Investment, IMM Investment, TimeFolio Asset Management, DCVC Bio and Sequoia Capital. The spinout had raised $8.5m in a 2018 seed round co-led by SK and DCVC Bio that included…
